On July 9, 2026, Femtech Insider reported that Estonia-based Muun Health secured a €700K grant from Enterprise Estonia to advance its Smart Patch Platform, a wearable designed to measure female sex hormones multiple times a day from interstitial fluid. The grant is part of a broader €1 million project focused on developing the sensor's "bioselective layer" — the component that enables real-time hormone readings — and positions Muun in the emerging race to make continuous hormone monitoring as routine as continuous glucose monitoring has become for diabetes.

Why It Matters

Continuous hormone monitoring is arguably the next frontier in femtech: the category that could do for fertility, perimenopause, and reproductive health what CGMs did for metabolic health. Direct, real-time hormone data would sharpen fertility-window prediction, perimenopause staging, and PCOS/endocrine management — and it directly threatens the current generation of algorithm-and-strip products (Natural Cycles, Clue, Oova) that infer hormone status rather than measure it. Muun's grant is small, but it signals that European public funders now see hormone-sensing hardware as strategically important, and it adds a credible hardware player to a race — alongside Oova, Clair Health, and others — where whoever ships an accurate, affordable continuous monitor first could reset the entire femtech data stack.

The pitch is a clean one: instead of urine strips, single-point blood draws, or basal-temperature proxies, Muun's patch reads hormone levels directly and transmits the data to a companion mobile app, offering women and clinicians real-time insight into ovulation and reproductive status. "Muun Health is on a mission to advance women's health quality with a novel continuous hormone monitor that gives both women and clinicians actionable data to make timely, informed decisions," the company said. Founded in 2023 by Kerli Luks, the startup has framed itself as building "a one of a kind wearable biosensor for women."

The grant follows Muun's €545K pre-seed round in late 2025, backed by Greiner Innoventures and The Better Fund Community Business Angels. That cumulative funding remains modest, but the category momentum is real: Muun joins a growing cohort chasing continuous hormone monitoring, a space that has drawn notable activity — including Oova's recent integration with Oura to connect hormone data with sleep and symptom tracking, and Clair Health's hormone-wearable work. The technical bar is high (miniaturizing a reliable, bioselective hormone sensor is hard), which is exactly why the Enterprise Estonia money is earmarked for the sensing layer rather than marketing.

For a femtech market that has spent a decade building around algorithms layered on top of indirect signals (temperature, LH strips, cycle history), a direct-measurement wearable would be a step-change — if the accuracy holds up outside the lab.

Sources

Update — 2026-07-10

Initial entry — story first created.